Camena Bioscience logo — Unlocking access to genes with unparalleled accuracy

Camena Bioscience

Unlocking access to genes with unparalleled accuracy

Founded 2016 United Kingdom Cambridge, United Kingdom 23 employees Series A Total: $7.90M Biotechnology, Health Care

General Information

Company Name Camena Bioscience
Founded Year 2016
Location United Kingdom Cambridge, United Kingdom
Founders / Decision Makers
Team member
Employees 23
Industries Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, Platform, On Demand
Revenue Model Product Sales, Service Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Camena Bioscience. To contact Camena Bioscience, visit camenabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Camena Bioscience compare?

A PDF of Camena Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Camena Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Camena Bioscience

Camena Bioscience, headquartered in the United Kingdom and founded in 2016, is an emerging player in the Biotechnology and Health Care industries. The company lives by its slogan, "Unlocking access to genes with unparalleled accuracy," positioning itself as a pivotal enabler for synthetic biologists.

Camena focuses on producing complex gene sequences, a capability crucial for various sectors including pharmaceuticals, agriculture, and diagnostics. These gene sequences are typically difficult to create, offering a distinct advantage to researchers engaged in the synthetic biology revolution. While the company operates out of Cambridge, UK, it boasts a global clientele.

Their most recent financial milestone was securing a £7.90M Series A investment from Mercia Asset Management as of 03 July 2023. This significant investment underscores the market's confidence in Camena's innovative technology and growth potential.

Business keywords: Synthetic Biology, Gene Synthesis, Nucleic Acid Synthesis, Pharmaceuticals, Agriculture, Diagnostics, DNA Synthesis, RNA Synthesis, XNA Synthesis, Genetic Engineering, Research Tools, Biotech Tools, Gene Sequencing, Bioengineering

Services & Products

DNA validation and synthesis
Accelerating drug discovery
CRISPR and Cas12a constructs production
Design and manufacture of cell and gene therapies
AI-driven antibody discovery

Target Customers

Pharmaceutical Companies Biotech Laboratories Life Sciences Research Institutions Genomic Research Facilities

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A £7.90M 1
Mercia Asset Management
03 Jul 2023

Camena Bioscience Alternatives & Competitors

View All Alternatives
Camena Bioscience vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
Camena Bioscience vs
Twist Bioscience
Twist Bioscience United States

Synthetic DNA for Health & Sustainability

IPO
1317 employees
Biotechnology, Health Care
Camena Bioscience vs

Transforming how molecular biology translates to human health, personalized medicine and synthetic b...

Series C
132 employees
Biotechnology, Health Care

FAQ About Camena Bioscience

Unlocking access to genes with unparalleled accuracy
Camena Bioscience was founded in 2016.
Camena Bioscience is headquartered in Cambridge, United Kingdom.
Camena Bioscience operates in Biotechnology and Health Care. Its work centres on Synthetic Biology, Gene Synthesis, Nucleic Acid Synthesis and Pharmaceuticals. Its customers include Pharmaceutical Companies, Biotech Laboratories and Life Sciences Research Institutions.
Camena Bioscience has a B2B, Platform and On Demand business model. Its revenue comes from Product Sales, Service Fee and Project Based.
Camena Bioscience has approximately 23 employees.
Camena Bioscience has completed 1 funding round, raising a total of $7.90M. The latest funding stage is Series A.
Camena Bioscience offers: DNA validation and synthesis, Accelerating drug discovery, CRISPR and Cas12a constructs production, Design and manufacture of cell and gene therapies, AI-driven antibody discovery.
Top alternatives and competitors to Camena Bioscience include Synbio Technologies, Twist Bioscience, DNA Script, Molecular Assemblies, Inc., Integrated DNA Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Camena Bioscience and Synbio Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Camena Bioscience, https://bouncewatch.com/company/camena-bioscience, updated 23 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes